

STUDY OF MORBIDITY PATTERN IN CHILDREN
WITH TRANSFUSION DEPENDENT
THALASSEMIA

Thesis

Submitted for Partial Fulfillment of M.Sc
Degree
in Pediatrics

By

Heba Tallah Ahmed Ali Elawa

M.B., B. Ch.

Faculty of Medicine -Ain Shams University

Under supervision of

Prof. Galila Mohamed Mokhtar

Professor of Pediatrics

Faculty of Medicine –Ain Shams University

Prof. Mohsen Gadallah

Professor of Public Health and Community

Faculty of Medicine – Ain Shams University

Dr. Nayera Hazaa Khalil El Sherif

Lecturer of Pediatrics

Fauctly of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University

2011

دراسة معدل الإصابة بالمضاعفات في الأطفال

المصابين بمرض انيميا البحر المتوسط

رسالة

توطئة للحصول على درجة الماجستير في طب الأطفال

مقدمة من

الطبيبة / هبة الله أحمد على عليوة

بكالوريوس الطب والجراحة

كلية الطب - جامعة عين شمس

تحت إشراف

الأستاذ الدكتور / جليلة محمد مختار

أستاذ طب الأطفال

كلية الطب - جامعة عين شمس

الأستاذ الدكتور / محسن جاد الله

استاذ الصحة العامة والمجتمع

كلية الطب - جامعة عين شمس

الدكتورة / نيرة هزاع خليل الشريف

مدرس طب الأطفال

كلية الطب - جامعة عين شمس

كلية الطب - جامعة عين شمس

٢٠١١

SUMMARY

Beta-thalassaemia represents a group of recessively inherited haemoglobin disorders characterized by deficient synthesis of the β globin chain. The homozygous state results in severe anaemia in infancy which requires regular blood transfusion.

The most important forms of thalassemia result from autosomal mutant genes that reduce the rate of synthesis of α and β chains of Hb A, designated α and β thalassemia respectively.

In Egypt, β -thalassemia is the commonest form of chronic hemolytic anemia among Egyptian children.

Thalassaemia is the most common monogenic disorder in the world. it is present in all ethnic groups. Therefore it is estimated that each year more than 5000 children are born with transfusion dependent β -thalassaemia. In the last decade the average lifespan of these patients was not more than 10years. The combination of blood transfusion and chelation therapy has dramatically prolonged the life expectancy of these patients, thus transforming thalassaemia from a rapidly fatal disease of childhood to a chronic disease compatible with a prolonged life.

Acknowledgment

First of all, I would like to thank "Allah" who granted me the strength to accomplish this work.

Words fail to express my deepest gratitude and appreciation to Prof. Galila Mohamed Mokhtar, Professor of Pediatrics, Faculty of Medicine, Ain Shams University for giving me the opportunity to work under his meticulous supervision and for his excellent guidance and powerful support.

My deepest thanks and appreciation go to Prof. Mohsen Gadallah, Professor of Public Health and Community, Faculty of Medicine – Ain Shams University, who honored me by her great supervision, valuable guidance and precious time.

I would like to express my true thanks to Dr. Nayera Hazaa Khalil El Sherif, Lecturer of Pediatrics, Faculty of Medicine - Ain Shams University, for her great guidance and advices throughout this work and fruitful suggestions without which this work would have never been accomplished.

I am also very grateful to all pediatric hematology clinic staff for the facilities they offered in achieving the patients' medical records and for their sincere cooperation.

My true love and warmest gratitude go Last but not by any means least, I would like to express my warm gratitude to my Mother, father Husband, my lovely child and to all my family, who were, and still always be, by my side and without whom I would have never been able to accomplish this work. Last but not least, I would like to express my gratitude to my patients and their families and to every person who helped me while performing this work.



Heba Ahmed

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَأَنْزَلَ اللَّهُ
عَلَيْكَ الْكِتَابَ
وَالْحِكْمَةَ
وَعَلَّمَكَ مَا لَمْ
تَكُنْ تَعْلَمُ
وَكَانَ فَضْلُ
اللَّهِ عَلَيْكَ
عَظِيمًا

صدق الله العظيم

سورة النساء آية

(١١٣)

List of Contents

Title	Page No.
<i>Introduction</i>	<i>1</i>
<i>Aim of the Work.....</i>	<i>3</i>
<i>Review of Literature</i>	
▪ <i>Beta-Thalassemia.....</i>	<i>4</i>
▪ <i>Morbidity and Mortality in Thalassemia Major.....</i>	<i>49</i>
<i>Patients and Methods.....</i>	<i>109</i>
<i>Results</i>	<i>125</i>
<i>Discussion</i>	<i>169</i>
<i>Summary.....</i>	<i>213</i>
<i>Conclusion.....</i>	<i>218</i>
<i>Recommendations</i>	<i>219</i>
<i>References</i>	<i>222</i>
<i>Arabic summary</i>	

List of Tables

Table No.	Title	Page No.
Table (1):	Demographic and clinical data of the studied patients	125
Table (2):	Mean Serum Ferritin Level in the year prior evaluation of the studied patients.....	126
Table (3):	Cardiovascular morbidities among beta Thalassemia patients	127
Table (4):	Renal morbidities among B thalassemia patients	128
Table (5):	Hepatic morbidities among B thalassemia patients	129
Table (6):	Bone mineral density abnormalities among B thalassemia patient.	130
Table (7):	Endocrinal morbidities among B thalassemia patients:	131
Table (8):	Iron chelation therapy given to the studied patients over the last 10 years	132
Table (9):	Comparison between the Different Iron Chelationtherapy groups (ICT) as regard the compliance.	133
Table (10):	Side effects of deferiprone among the studied patients	134
Table (11):	Side effects of ICL670 among the studied patients	135
Table (12):	Side effects of desferal among the studied patients	136
Table (13):	Comparison between both groups as regard Demographic and clinical Data.....	137

List of Tables (cont...)

Table No.	Title	Page No.
Table (14):	Comparison between both groups as regard theFrequency of Blood Transfusion and Splenectomy.....	138
Table (15):	Comparison between both groups as regard anthropometric measurements and Puberty.	139
Table (16):	Comparison between both groups as regard the cardiac, hepatic, renal, endocrinal morbidities and decreased bone mineral density.	140
Table (17):	Comparison between both groups as regard Iron Chelation therapy used in the last 2 years.....	142
Table (18):	Comparison between both groups as regard Iron Chelation therapy used in the last 10 years.	143
Table (19):	Comparison between both groups as regard Compliance to Iron Chelationtherapy.....	144
Table (20):	Comparison between both groups as regard the prevelance of Chelating Agent-Related Adverse Effects	145
Table (21):	Comparison between both groups as regard the Mortality rate.....	146
Table (22):	Comparison between ICT groups as regard the Demographic Data	147
Table (23):	Comparison between ICT groups as regard Blood Transfusion and Splenectomy.....	148
Table (24):	Comparison between ICT groups as regard the Growth and Puberty	149

List of Tables (cont...)

Table No.	Title	Page No.
Table (25):	Comparison between ICT groups as regard the Serum Ferritin.....	150
Table (26):	Comparison between ICT groups as regardthe prevalence of cardiac, hepatic, renal, endocrinal morbidities and decreased bone mineral density.....	151
Table (27):	Correlation between the mean ferritin in the year before evaluation and renal, hepatic, bone density abnormalities.	152
Table (28):	Correlation between between the mean ferritin in the year before evaluation and endocrinal morbidities.....	153
Table (29):	Correlation between the mean ferritn in the year before evaluation and the cardiovascular complications.....	154
Table (30):	Correlation between morbidities and age of onset of the disease among the studied patients.....	155
Table (31):	Correlation between morbidities and gender among the studied patients.....	156
Table (32):	Correlation between ferrtin trend and compliance	157
Table (33):	Correlation between the meanferritn in the year before evaluation andand mortality rate.	158
Table (34):	Correlation between age, age at diagnosis, gender and mortality rate.	159
Table (35):	Correlation between compliance and mortality rate among the studied patients.....	160

List of Tables (cont...)

Table No.	Title	Page No.
Table (36):	Correlation between the compliance to chelatortherapy in the year before evaluation and renal, hepatic, bone density abnormalities.....	161
Table (37):	Correlation between the compliance to chelatortherapy in the year before evaluation and endocrinal abnormalities.	162
Table (38):	Correlation between thecompliance to chelator therapy the year before evaluation and the cardiovascular complications.....	163
Table (39):	Correlation between the frequency of blood transfusion in the year before evaluation and renal, hepatic, bone density abnormalities.....	164
Table (40):	Correlation between the frequency of blood transfusion in the year before evaluation andendocrinal abnormalities.	165
Table (41):	Correlation between thefrequency of blood transfusion in the year before evaluation and the cardiovascular complications.....	166
Table (42):	The correlation between the compliance and different types of chelatorsin the year before evaluation:	167

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	The geographical distribution of the thalassemias and the more common, inherited structural hemoglobin abnormalities.....	5
Fig. (2):	Structure of hemoglobin.....	6
Fig. (3):	a. The facial appearance of a child with α -thalassemia major. b. The skull X-ray in α -thalassemia major	13
Fig. (4):	Management of thalassemia and related complications	14
Fig. (5):	Smear of normal RBC on the left and β thalassemia intermedia RBC on the right	16
Fig. (6):	The classic "hair on end" appearance on plain skull radiographs of a 9-year-old girl with thalassemia intermedia showing the Cranium (Extensive macrocephally with widened diploe, thinned tabula externa and subperiosteal spicule)	22
Fig. (7):	Excessive iron in a bone marrow preparation	23
Fig. (8):	Cardiovascular morbidities among beta Thalassemia patients	127
Fig. (9):	Renal morbidities among B thalassemia patients	128
Fig. (10):	Morbidities among the studied patients	131
Fig. (11):	Iron chelation therapy given to the studied patients in the last 10 years	132
Fig. (12):	Survival ratesamong the studied patients.	168

List of Abbreviations

γ	<i>Gamma</i>
α	<i>Alpha</i>
β	<i>Beta</i>
ζ	<i>Zeta</i>
ε	<i>Epsilon</i>
Hb	<i>Hemoglobin</i>
IV	<i>Intravenous</i>
SC	<i>Subcutaneous</i>
TLC	<i>Total leucocytic count</i>
Plt	<i>Platelet</i>
T. bil	<i>Total bilirubin</i>
D. bil	<i>Direct bilirubin</i>
EF	<i>Ejection fraction</i>
SD	<i>Standard deviation</i>
LVEF	<i>Left ventricular ejection fraction</i>
DFO	<i>Defereprone</i>
RDW	<i>Red cell distribution width</i>
rHuEPO	<i>Recombinant human erythropoietin</i>
CPT	<i>Carnitinepalmitoyltransferase</i>
OCTF	<i>Organic carnitine transporter family</i>
IGF-1	<i>Insulin growth factor 1</i>

INTRODUCTION

Thalassemia is a group of chronic hereditary hemolytic anemias particularly common in persons of Mediterranean, African, and South Asian ancestry in which there is decreased synthesis of one or more hemoglobin polypeptide chains (*Palma et al., 2005*).

Generally, the estimated prevalence is 16% in people from Cyprus, 3-14% in Thailand and 3-8% in populations from Bangladesh, China, India, Malaysia and Pakistan. A very low prevalences has been reported from people in Africa (0.9%) with those in North Africa having the highest prevalence and northern Europe 0.4% (*Wambuas et al., 2006*).

Depending on the genes involved, thalassemia is classified as Alpha-Thalassemia or B Thalassemia which is further classified into B thalassemia major and B Thalassemia intermedia. Thalassemia major presents typically within the first year of life and patients subsequently require ongoing transfusions to survive, Thalassemia intermedia presents late in life and patients may be transfusion independent or require only sporadic transfusion (*Forget et al., 2005*).

Quality and duration of life of transfusion-dependent B Thalassemia patients have been transformed over the last ten years with life expectancy increasing well into the third and the forth decades. Nevertheless, the life prolongation

discloses several complications partly due to the underlying disorders, partly related to the conventional treatment with blood transfusions and to iron overload (*Borgna et al., 2003*).

Complications of thalassemia major are mostly due to iron overload caused by frequent blood transfusions, and include heart failure, infections, hypogonadism, infertility, diabetes mellitus and hypothyroidism (*Olivieri, 1999*).

Cardiac complications remain the most important in determining the survival of B -Thalassemia major patients, it should be emphasized that they are not restricted to the effect of anemia and iron loading although they are by far the most important factors (*Piga and Longo, 1997*).

Thalassemia patients have an increased risk of infections because of splenectomy, iron load and blood born infections particularly viral (*Adam, 1998*).

Endocrine abnormalities are among the common complications of thalassemia despite good chelation therapy. Delayed puberty and defective function of the hypothalamic /pituitary axis occurs in approximately 56% of both male and female patients (*Cohen, 2000*).

Osteoporosis is a multi- factorial complication and is very common in adult thalassemia patients of both sexes, it requires an adequate management in order to prevent progressive disease and fractures (*Locatelle, 2004*).

AIM OF THE WORK

The aim of this work is to study the morbidity patterns of transfusion-dependent thalassemia patients, and compare the outcomes of these patients in relation to age of onset, type, duration and compliance to iron chelation therapy and frequency of blood transfusion.